Saltissi HD 2002.

Methods	Study design: stratified, placebo‐controlled RCT Time frame: NR Follow‐up period: 24 weeks
Participants	Country: Australia Setting: single centre Inclusion criteria: HD or CAPD for 9 months, non‐HDL > 135 mg/dL, LDL > 116 mg/dL, TG < 600 mg/dL Number (treatment/control): 22/12 Age (mean ± SD) years: treatment group (59.5 ± 13.9); control group (62.8 ± 9.6) Sex (M/F): treatment group (6/16); control group (5/7) Exclusion criteria: impaired hepatic function; elevated creatine phosphokinase; myocardial insufficiency; uncontrolled DM; active infection; malignancy; treatment with other lipid‐lowering agents
Interventions	Treatment group Simvastatin Dose: 5 mg and dose was increased to 20 mg as needed to achieve non‐HDL < 135 mg/dL Treatment duration: 24 weeks Control group Placebo
Outcomes	Lipid parameters (TC, LDL, HDL, TG, Lp (a), Apo A1)
Notes	This is the same study as Saltissi PD 2002 Industry funding received
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	NR
Allocation concealment (selection bias)	Unclear risk	NR
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Double‐blinded
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	NR
Incomplete outcome data (attrition bias) All outcomes	High risk	42/57 patients (74%) completed study
Selective reporting (reporting bias)	Low risk	Published reports included all expected outcomes
ITT analysis	High risk	Not conducted